Clinical Trial

A Study of Brenipatide in Participants With Alcohol Use Disorder

Study acronym: RENEW-ALC-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.
Protocol Amendment History 1 change
notable Trial sites expanded: 114 -> 117 locations 2026-05-23
Trial Details
NCT Number NCT07219953
Lead Sponsor Eli Lilly and Company
Conditions Alcohol Use Disorder
Enrollment 1,100 participants
Start Date 2025-10-16
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-06